Biomaterial Database

T helper type-2 cytokine responses: potential therapeutic targets. 2003

Andrew G Jarnicki, and Padraic G Fallon

Department of Biochemistry, Trinity College, Dublin 2, Ireland.

T helper (Th)2 cell-mediated immune responses are associated with parasitic helminth infections and atopic disorders. The production of interleukin (IL)-4, IL-5, IL-9 and/or IL-13 by Th2 cells mediates a range of responses that can be protective or pathogenic. Progress has recently been made in elucidating the mechanism of Th2 immunity, which has therapeutic potential for the treatment of allergic diseases.

UI	MeSH Term	Description	Entries
D006967	Hypersensitivity	Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007167	Immunotherapy	Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.	Immunotherapies
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D016207	Cytokines	Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.	Cytokine
D016503	Drug Delivery Systems	Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.	Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D018121	Receptors, Cytokine	Cell surface proteins that bind cytokines and trigger intracellular changes influencing the behavior of cells.	Cytokine Receptors,Cytokine Receptor,Receptors, Cytokines,Cytokines Receptors,Receptor, Cytokine
D018417	Th1 Cells	A subset of helper-inducer T-lymphocytes which synthesize and secrete INTERLEUKIN-2; INTERFERON-GAMMA; and INTERLEUKIN-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.	T Helper 1 Cells,TH-1 Cells,Type 1 Helper T Cells,Cell, TH-1,Cell, Th1,Cells, TH-1,Cells, Th1,TH 1 Cells,TH-1 Cell,Th1 Cell
D018418	Th2 Cells	A subset of helper-inducer T-lymphocytes which synthesize and secrete the INTERLEUKINS IL-4; IL-5; IL-6; and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.	T Helper 2 Cell,T Helper2 Cell,TH-2 Cell,Th2 Cell,Type-2 Helper T Cell,T Helper 2 Cells,T Helper2 Cells,TH-2 Cells,Type-2 Helper T Cells,Cell, T Helper2,Cell, TH-2,Cell, Th2,Cells, T Helper2,Cells, TH-2,Cells, Th2,TH 2 Cell,TH 2 Cells,Type 2 Helper T Cell,Type 2 Helper T Cells
D020868	Gene Silencing	Interruption or suppression of the expression of a gene at transcriptional or translational levels.	Gene Inactivation,Inactivation, Gene,Silencing, Gene